<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01865253</url>
  </required_header>
  <id_info>
    <org_study_id>087/12</org_study_id>
    <secondary_id>1034397</secondary_id>
    <nct_id>NCT01865253</nct_id>
  </id_info>
  <brief_title>Renal Denervation for Complicated Hypertension</brief_title>
  <acronym>RDNP-2012-03</acronym>
  <official_title>Renal Denervation for Complicated Hypertension (RDNP-2012-03)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baker IDI Heart and Diabetes Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Baker IDI Heart and Diabetes Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an observational proof of concept study investigating the safety and effectiveness of
      renal denervation to lower blood pressure in people whose blood pressure is not adequately
      controlled due to:

        -  intolerance to antihypertensive medication

        -  inability to take antihypertensive medication due to planned pregnancy

        -  renal artery stenosis

        -  chronic kidney disease

        -  non-compliance to antihypertensive medication

      A total of 125 participants, 25 from each of the groups mentioned above will be recruited to
      the study.

      The duration of this study is 36 months.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    No new participants enrolled. Protocol superseded.
  </why_stopped>
  <start_date>May 2012</start_date>
  <completion_date type="Actual">March 2015</completion_date>
  <primary_completion_date type="Actual">March 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in average office blood pressure</measure>
    <time_frame>baseline to 6 months post procedure</time_frame>
    <description>Change in systolic and diastolic average office blood pressure from baseline to 6 months post procedure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blood pressure control</measure>
    <time_frame>baseline to 6 months post procedure</time_frame>
    <description>Percentage of patients who achieved BP target at 6 months post procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of drugs required to reach target blood pressure</measure>
    <time_frame>baseline to 6 months post procedure</time_frame>
    <description>Number of drugs required to reach target blood pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to achieve blood pressure target</measure>
    <time_frame>baseline to 6 months post procedure</time_frame>
    <description>Time to achieve blood pressure target</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in sympathetic nerve activity</measure>
    <time_frame>baseline to 6 months post procedure</time_frame>
    <description>Change in muscle sympathetic nerve activity, renal and whole body Noradrenaline (NA) spillover</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in left ventricular structure and function</measure>
    <time_frame>baseline to 6 months post procedure</time_frame>
    <description>Change in left Ventricular mass index, Ejection Fraction, diastolic filling</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Quality of life</measure>
    <time_frame>baseline to 6 months post procedure</time_frame>
    <description>Change in Quality of life as assessed by relevant questionnaires</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in serum and urine Biochemistry</measure>
    <time_frame>baseline to 6 months post procedure</time_frame>
    <description>Plasma renin activity, aldosterone, estimated Glomerular Filtration Rate(eGFR), Urinary Albumin Creatinine Ratio (UACR), inflammatory markers, 24hour urine creatinine clearance, sodium, fasting glucose, fasting insulin, c peptide, Homeostasis Model Assessment (HOMA) index, lipid profile.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in markers of arterial stiffness</measure>
    <time_frame>baseline to 6 months</time_frame>
    <description>Change in markers of arterial stiffness including Augmentation Index (AI) and Pulse Wave Velocity (PWV)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Renal Denervation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Renal Denervation treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Renal Denervation</intervention_name>
    <description>Renal Denervation</description>
    <arm_group_label>Renal Denervation</arm_group_label>
    <other_name>Symplicity Renal Denervation Catheter</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  BP ≥140/90 mmHg (or ≥130/80 mmHg for patients with diabetes)

          -  Intolerance to ≥2 antihypertensive drug classes

          -  Inability to take Angiotensin-Converting-Enzyme Inhibitor (ACEI), Angiotensin II
             Receptor Blockers (ARBs) or Direct Renin inhibitors (DRIs) due to planned pregnancy

          -  Renal artery stenosis

          -  Chronic Kidney Disease

        Exclusion Criteria:

          -  renal artery anatomy ineligible for treatment

          -  individual has had myocardial infarction, unstable angina or cerebrovascular accident
             within 6 months of screening visit

          -  female participants of childbearing potential must have negative pregnancy test prior
             to treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Markus P Schlaich, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Baker IDI Heart &amp; Diabetes Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Baker IDI Heart &amp; Diabetes Institute</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 27, 2013</study_first_submitted>
  <study_first_submitted_qc>May 27, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 30, 2013</study_first_posted>
  <last_update_submitted>July 20, 2016</last_update_submitted>
  <last_update_submitted_qc>July 20, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 22, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>renal denervation</keyword>
  <keyword>blood pressure</keyword>
  <keyword>cardiovascular risk</keyword>
  <keyword>target organ damage</keyword>
  <keyword>sympathetic activity</keyword>
  <keyword>chronic kidney disease</keyword>
  <keyword>non-compliance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

